Clinical trials
Every registered trial of Thymopentin (TP-5)
10 studies, 1 still enrolling.
Plain-Language Summary
Plain-language reading of the public trial registries.
In short
- Very little human research on Thymopentin (TP-5) has been registered.
- 10 registered studies in total.
- 1 is still enrolling people, so this is active research, not just history.
What kind of research
- 10 studies actually gave the peptide to volunteers and measured what happened. This is the kind of study that can show whether something works.
- About 333 people took part in those.
How far along it is
- 2 trials have reached phase 3 or 4 — the large, late-stage trials regulators rely on to approve a drug.
- 1 has published results in the medical literature that anyone can read.
- The research spans 3 countries.
A registered trial is a plan, not a result. Registration means a study was declared in advance; it says nothing about whether the peptide worked, and a trial can be registered and then abandoned.
Filter
Showing 10 of 10 trials for Thymopentin (TP-5).
Phase1 First in Human Ascending Dose Study to Evaluate the Safety and Tolerability of FC-12738 in Health Adults
Neurodegenerative Disease Research Inc
Safety Issues · Tolerance
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors (PRaG9.0)
Second Affiliated Hospital of Soochow University
Carcinoma · Solid Tumor
Study of Thymopentin in Patients After Curative Resection of Small Hepatocellular Carcinoma
Fudan University
Hepatocellular Carcinoma
- NCT00002289Completed
The Effects of Thymopentin on HIV Infectivity of Blood Cells and Semen in HIV-Infected Patients
Immunobiology Research Institute
HIV Infections
- NCT00002049Completed
Double Blind Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients
Immunobiology Research Institute
HIV Infections
- NCT00002066Completed
Double Blind Study of Thymopentin Effects on Patients With HIV-1 Infection
Immunobiology Research Institute
HIV Infections
Double-Blind Study of Timunox (Thymopentin) in Asymptomatic HIV-Infected Patients Receiving Either Mono (AZT or ddI) or Combination (AZT / ddI or AZT / ddC) Anti-Retroviral Therapy
Immunobiology Research Institute
HIV Infections
A Study of Timunox (Thymopentin) in HIV-Infected Patients Receiving Other Anti-HIV Drugs
Immunobiology Research Institute
HIV Infections
- NCT00002050Completed
A Study of Thymopentin Effects on HIV-1 Infectivity of Blood Mononuclear Cells and Semen in HIV Infected Patients
Immunobiology Research Institute
HIV Infections
- NCT00002051Completed
Double Blind Study of Thymopentin Effects on Patients With HIV-1 Infection
Immunobiology Research Institute
HIV Infections
Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered in more than one registry is counted once. A study is listed when Thymopentin (TP-5) is named as an intervention. A registered trial is a plan, not a result — registration says nothing about whether the peptide worked.